




FIG. 1




FIG. 2




FIG. 3A




FIG. 3B




FIG. 4A




FIG. 4B




FIG. 5




FIG. 6A




FIG. 6B




FIG. 7A




FIG. 7B




FIG. 7C




FIG. 7D




FIG. 7E




FIG. 7F




FIG. 8




FIG. 9A




FIG. 9B




FIG. 9C




FIG. 9D




FIG. 10A




FIG. 10B




FIG. 10C




FIG. 11A




FIG. 11B




FIG. 11C




FIG. 12A




FIG. 12B




FIG. 12C




FIG. 12D




FIG. 12E

SIRP α Binding
Region
(PDB: 2JJS)

Magrolimab Binding
Region
(PDB: 5IWL)

TY21446 Binding
Region




FIG. 13A




FIG. 13B




FIG. 14A

Relative CD47 Receptor Occupancy
in Normal Tissues and Tumors in hCD47 Knock-in Mice
Bearing MDA-MB-231 Tumors (24h after dosing; n=3)




FIG. 14B




FIG. 14C




FIG. 14D

OE19 in CB17 SCID




FIG. 15A

MDA-MB-231 in CB17 SCID




FIG. 15B




FIG. 15C




FIG. 15D




FIG. 15E




FIG. 16A




FIG. 16B




FIG. 17A




FIG. 17B